Jonathan Reyes/CNN
Now playing
01:39
Your brain on marijuana
KVVU
Now playing
00:59
Pot yoga: Highly relaxing and then some
CNN
Now playing
01:22
The dangers of synthetic marijuana
An Israeli agricultural engineer inspects marijuana plants at the BOL (Breath Of Life) Pharma greenhouse in the country's second-largest medical cannabis plantation, near Kfar Pines in northern Israel, on March 9, 2016.
The recreational use of cannabis is illegal in the Jewish state, but for the past 10 years its therapeutic use has not only been permitted but also encouraged. Last year, doctors prescribed the herb to about 25,000 patients suffering from cancer, epilepsy, post-traumatic stress and degenerative diseases. The purpose is not to cure them but to alleviate their symptoms. Forbidden to export its cannabis plants, Israel is concentrating instead on marketing its agronomic, medical and technological expertise in the hope of becoming a world hub in the field.
 / AFP / JACK GUEZ        (Photo credit should read JACK GUEZ/AFP/Getty Images)
JACK GUEZ/AFP/Getty Images
An Israeli agricultural engineer inspects marijuana plants at the BOL (Breath Of Life) Pharma greenhouse in the country's second-largest medical cannabis plantation, near Kfar Pines in northern Israel, on March 9, 2016. The recreational use of cannabis is illegal in the Jewish state, but for the past 10 years its therapeutic use has not only been permitted but also encouraged. Last year, doctors prescribed the herb to about 25,000 patients suffering from cancer, epilepsy, post-traumatic stress and degenerative diseases. The purpose is not to cure them but to alleviate their symptoms. Forbidden to export its cannabis plants, Israel is concentrating instead on marketing its agronomic, medical and technological expertise in the hope of becoming a world hub in the field. / AFP / JACK GUEZ (Photo credit should read JACK GUEZ/AFP/Getty Images)
Now playing
02:28
Why weed is stuck in a legal limbo
John Lustig and his wife Anne learn about cannabis lotions
Jen Christensen, CNN
John Lustig and his wife Anne learn about cannabis lotions
Now playing
02:36
Seniors get on board the Cannabus
 GO WITH AFP STORY by Desiree Martin A picture taken on April 12, 2013 shows plants of marijuana at the plantation of the Sibaratas Med Can association in Mogan on the southwest coast of the island of Gran Canaria. The plants grow from cuttings for approximately two months and then blossom before being harvested, dried, stored in jars for a month and later processed to be consumed on site. Spanish law prohibits the possession of soft drugs like cannabis in public and its growth to be sold for profit is illegal. But the law does tolerate growing cannabis for personal use and its consumption in private. Dozens of private marijuana smoking clubs operate across Spain that take advantage of this legal loophole that serve cannabis users who do not want to get their drugs from the streets. AFP PHOTO / DESIREE MARTIN (Photo credit should read DESIREE MARTIN/AFP/Getty Images)
DESIREE MARTIN/AFP/Getty Images
GO WITH AFP STORY by Desiree Martin A picture taken on April 12, 2013 shows plants of marijuana at the plantation of the Sibaratas Med Can association in Mogan on the southwest coast of the island of Gran Canaria. The plants grow from cuttings for approximately two months and then blossom before being harvested, dried, stored in jars for a month and later processed to be consumed on site. Spanish law prohibits the possession of soft drugs like cannabis in public and its growth to be sold for profit is illegal. But the law does tolerate growing cannabis for personal use and its consumption in private. Dozens of private marijuana smoking clubs operate across Spain that take advantage of this legal loophole that serve cannabis users who do not want to get their drugs from the streets. AFP PHOTO / DESIREE MARTIN (Photo credit should read DESIREE MARTIN/AFP/Getty Images)
Now playing
02:11
Will recreational marijuana soon be legal nationwide?
CNN
Now playing
02:35
The weed distributor fighting 'big marijuana'
nfl marijuana use goodell fitzgerald bts_00001009.jpg
NFL Network
nfl marijuana use goodell fitzgerald bts_00001009.jpg
Now playing
00:48
Goodell addresses NFL ban on marijuana use
CNN Illustration/Getty Images
Now playing
02:00
California pushing back on Sessions' pot memo
AG Sessions, Rosenstein, Gore Civil Rights Ceremony
CNN
AG Sessions, Rosenstein, Gore Civil Rights Ceremony
Now playing
01:47
Sessions to rescind Obama-era marijuana policy
Jeff Sessions NAAG remarks medical marijuana_00004720.jpg
CNN
Jeff Sessions NAAG remarks medical marijuana_00004720.jpg
Now playing
01:12
Sessions: Marijuana won't fix opioid epidemic
california weed vs whiskey sidner pkg _00001109.jpg
CNN
california weed vs whiskey sidner pkg _00001109.jpg
Now playing
04:07
Will weed be bigger than whiskey?
CNN
Now playing
02:24
Designer marijuana boost THC potency
marijuana edibles high profits_00000130.jpg
marijuana edibles high profits_00000130.jpg
Now playing
01:09
Is eating marijuana riskier than smoking it?
history medical marijuana orig nws_00003424.jpg
history medical marijuana orig nws_00003424.jpg
Now playing
01:56
The quick hit history of medical marijuana
(CNN) —  

Cannabis-related products have flooded the market, making health claims about pain relief, immune function and anxiety and depression. But the US Food and Drug Administration says there is little known about how effective they are. On Friday, the FDA held its first hearing to assess the safety and efficacy of CBD products.

In opening the hearing Dr. Ned Sharpless, acting commissioner of the FDA, said despite the widespread use of such products “critical questions remain about the safety” of these items.

Products touting CBD and THC – two of the active ingredients in cannabis – can be found in foods, dietary supplements, and even cosmetics.

“While we have seen an explosion of interest in products containing CBD, there is still much that we don’t know,” said Sharpless.

CBD, also known as cannabidiol, is the ingredient in marijuana and hemp touted to have many medicinal benefits. It’s different from tetrahydrocannabinol or THC, the main psychoactive component of cannabis.

Sharpless pointed out that prior to the passage of last year’s farm bill, which removed hemp as a controlled substance, much of the research into cannabis looked at the plant as a whole, rather than specific components like CBD.

“When hemp was removed as a controlled substance, this lack of research, and therefore evidence, to support CBD’s broader use in FDA-regulated products, including in foods and dietary supplements, has resulted in unique complexities for its regulation, including many unanswered questions related to its safety,” he said.

Today’s hearing, he said, would inform the agency as it moved forward with determining how to regulate CBD.

’Only limited available information about CBD’

Last June, the FDA for the first time approved a cannabis plant-derived, CBD-based drug, Epidiolex, which is approved to treat two severe and rare forms of epilepsy: Dravet Syndrome and Lennox-Gastaut syndrome.

Dr. Amy Abernathy, principal deputy commissioner of the FDA and head of the agency’s CBD working group, said in a tweet last week, “The FDA has not approved any other CBD-containing products. We want consumers to be aware that there is only limited available information about CBD, including about its effects on the body.”

Witnesses from the supplement industry, researchers, doctors and patients are all expected to testify about their experiences with cannabis at Friday’s hearing. The agency will also make a docket available for public comments that will close on July 2.

In April, then-FDA commissioner Dr. Scott Gottlieb warned in a statement that “open questions remain regarding the safety” of widespread use of CBD products. He also noted there are concerns about a lack of standards around CBD concentrations in products and the possible impacts of long-term CBD use.

“It’s critical that we address these unanswered questions about CBD and other cannabis and cannabis-derived products to help inform the FDA’s regulatory oversight of these products,” he said. “Especially as the agency considers whether it could be appropriate to exercise its authority to allow the use of CBD in dietary supplements and other foods.”

It is illegal to introduce CBD or THC into the food supply or market it as a dietary supplement. Marijuana remains illegal under federal law. However, at least 10 states have moved ahead and legalized the purchase and possession of recreational marijuana while 33 states allow the use of medical marijuana.

A market in the billions

As states have liberalized the use of marijuana, CBD-related products such as oils, lotions, chocolates and even dog food have stormed the market.

Market analysts expect the hemp-derived CBD market alone to hit between $15-20 billion in the next five to six years.

“The industry is exploding, it’s growing in popularity every day. It’s so important for the FDA to get a regulatory handle on this,” said Jonathan Miller, general counsel for the US Hemp Roundtable, an industry-backed advocacy group. “There are bad products out there. There are products that make false claims. It’s important that FDA develop standards.”

Earlier this year, FDA sent warning letters to PotNetwork Holdings in Florida, Nutra Pure in Washington state and Advanced Spine and Pain in New Jersey for “making unsubstantiated claims related to more than a dozen different products and spanning multiple product webpages, online stores and social media websites.” These companies made claims that CBD could help with cancer and dementia.

Since 2015, the FDA has issued 48 similar type letters about the marketing of CBD products.

Miller said the industry wants regulation. “Our biggest enemy isn’t the FDA or the DEA, but CBD companies making false claims,” he said.

’The genie’ is ‘out of the bottle’

“There needs to be clear steps in informing the public that there is no science behind the generic claims made about CBD,” Dr. Yasmin Hurd, director of the Addiction Institute at Mount Sinai in New York and a cannabis researcher, wrote in an email to CNN.

But Hurd worries that the FDA is coming to the table too late.

“The market and the public have already let the genie out of the bottle and it will be difficult to put it back in without the FDA and government showing clear proof that there is evidence showing a negative health impact,” she said.

Get CNN Health's weekly newsletter

Sign up here to get The Results Are In with Dr. Sanjay Gupta every Tuesday from the CNN Health team.

While a timeline hasn’t been set by the FDA, Miller is hopeful that the FDA will prioritize creating regulations for cannabis-based products. He anticipates that CBD can be regulated both as a drug and as supplement, potentially based on dosing and concentration.

Maintaining a distinction between a medical research pathway and a supplements pathway is key, Hurd said.

“It is critical that the FDA consider making a distinct pathway to expedite CBD research to thus make it possible to quickly inform policy makers, patients and physicians about the potential health impact, dosing regimens, adverse effects as necessary for the development of any medication. It needs to be clear that such a pathway would be different from recreational or nutraceutical/supplement market.”

The FDA’s Sharpless agreed: “Drugs have important therapeutic value, and it is critical that we continue to do what we can to support the science needed to develop new drugs from cannabis.”